More accurate and personalized symptom load predictions. Comprehensive, easy-to-tune supportive care recommendations. A more productive, efficient patient connection. Designed by leading supportive oncologists. Training on NCI-designated cancer center patient data.
Supportive care fails when symptoms aren't predicted and care becomes reactive.
EO Care 360° addresses both sides of the problem at once. The clinician gets a symptom forecast and plan to tune and manage. The patient gets a clear plan, provides timely feedback and is more intelligently triaged when needed.
Symptoms managed before they peak mean fewer held treatment doses and fewer patients who stop early.
The spike that becomes an emergency is everyone's fear. Acute care avoided is the most direct saving there is.
A plan drafted for your signature, responsible and automated updates and fewer unplanned calls.
Care management reimbursements and incremental quality incentive payments driven by automated work.
Better plan for and minimize use of controlled substances. Ensure all team members see the entire symptom management picture.
Supportive care today is reactive. The symptom arrives, then the call, then the fix. A better forecast moves the whole sequence earlier, to the days where a small change still works.
The forecast runs on the regimen, her chart and her own answers, and it runs before the cycle does.
Support steps up on the ladder you already signed, on the day the model says it matters.
No unplanned call, no held dose, no visit that existed only because nobody saw it coming.
Bayesian models are used for recommendations and guidance. LLMs are only for writing, not deciding. Safety rules and clinician permissions/inputs override it all.
Sources of knowledge are the latest ASCO, ESMO and NCCN guidelines, thousands of de-identified NCI-designated tier 1 cancer center patient records, your patient's EMR data and your wisdom. And the platform learns your preferences over time.
All delivered via your existing EHR interface with customizable workflows.
EO began in supportive oncology doing one thing: scaled, evidence-based, clinically responsible cannabinoid care for patients at scale. Physicians at eight NCI-designated tier 1 cancer centers began referring patients to us.
The success we achieved (key results below) inspired our clinical partners to ask for a complete, multi-modal platform. We are currently training this platform further using anonymized patient data from a cancer center partner.
Real-world results from EO's clinician-guided cannabinoid care in supportive oncology settings. Observational data from routine care, not a randomized trial. Cost impacts from Milliman-validated cost savings report, estimated per patient per year.
Every rule in the system, and the clinical policy inside it, is reviewed and signed by one of them before it runs.
Chief Medical Officer
A pioneering palliative care clinician and researcher, Dr. Worster is currently Director, Supportive Oncology at Jefferson Health in Philadelphia. She is a graduate of Temple University School of Medicine and completed her fellowship in palliative care and pain management at MGH Brigham and Dana Farber Cancer Center in Boston.
Clinical Advisor
Dr. Strand is currently Chair of the Enterprise Center for Palliative Medicine and Associate Chair, Division of Community Internal Medicine, Geriatrics and Palliative Care at the Mayo Clinic in Rochester, MN. His clinical work is centered on managing pain and enhancing quality of life for those with cancer and other serious illnesses.
Clinical Advisor
A primary care physician and public health leader, Dr. Benjamin served as the 18th U.S. Surgeon General, providing critical guidance on national health issues and championing preventive care. She is the founder and CEO of the Bayou Clinic and sits on multiple boards, including those of Kaiser Permanente, Ascension Health and Doximity.
Chief Executive Officer
A longtime startup founder and investor in data-driven guidance platforms, Sean has focused for years on helping people and businesses make decisions in the context of uncertainty. He has deep expertise in digital and app-based startups, Bayesian and ML team formation, product commercialization and distribution.
Chief Experience Officer
A CX, design and marketing innovator, Dave co-founded, grew and sold two leading digital agencies (BEAM and Euro RSCG Circle). He has overseen product and experience design efforts for some of the largest and most innovative healthcare, financial services and consumer products brands in the world.
Head of Data Modeling
Kristen is an innovative quantitative and algorithmic modeler with experience across medical, biotech and financial services verticals. She is expert in Bayesian, AI and decision network model design, prototyping and performance evaluation.
Just complete the short form below and we will get right back to you with some times to consider.
A member of our team will be back to you within a day to coordinate scheduling. For any questions, email camila@eo.care.
Please fill out the contact form above and we will reach out to discuss options for a trial in Q1 2027.
EO 360° covers the care a patient can do or take at home: prescription medicines, over-the-counter medicines and supplements, integrative care such as acupuncture, exercise, mindfulness and massage, cannabinoid therapy guided by an EO clinician, and referrals such as physical therapy or counseling.
It addresses the common symptoms: nausea, fatigue, pain, nerve pain, constipation, diarrhea, sleep, anxiety, appetite, weight change, memory and focus, and sexual health. It does not suggest IV drugs, anything that must be given in clinic, or anything related to the oncology disease treatment itself. It works across cancer types, during treatment and after treatment ends.
No. A clinician reviews and approves every initial plan, and EO 360° never writes a prescription.
Once the plan is running, patient check-ins drive suggested adjustments. Your team decides how much the platform may change on its own, for example the dose of an over-the-counter medicine or a supplement within limits you set. New prescriptions, controlled substances and any possible drug interaction always come back to a clinician, and a reported warning sign reaches the care team right away.
A model that weighs the facts of each patient: cancer type, treatment drugs, where they are in the cycle, the area under treatment, other medicines, age, overall health, comorbidities and their own symptom reports. It estimates which symptoms are likely over the next 30 days and how severe they may be, so the team can act before a symptom builds. It also predicts which patients, should symptoms appear, are more likely to escalate into an urgent medical need, so your team can check in more often and escalate faster when needed.
The model started from published research, ASCO and other published guidelines, clinical trials and drug protocols, and is validated and tuned on an ongoing basis with NCI Comprehensive Cancer Center data across millions of patient records. As patients check in, each plan adjusts to what is actually happening, changing proactively to head off escalations from unmanaged symptoms.
Guidelines from NCCN, ASCO, MASCC, ESMO and the Society for Integrative Oncology; clinical trials and research reviews; FDA drug labels and safety warnings; and safety rules written and reviewed by our clinical team, including interaction checks. These sources are checked for updates on a regular schedule.
The platform also learns from how real patients respond over time, including our own data from more than 1,000 people with cancer and learning from millions of cancer patient records.
Yes. Every recommendation shows why it was made: the symptom it treats, how strong the evidence is, and the guideline or study behind it, along with any safety flags and the reason they were raised. You can also ask the model any question directly, and it will show its reasoning.
Cannabinoids are only suggested if the patient is open to it and cannabinoid-based care is legal in your state. An EO clinician guides their cannabinoid care, and the platform checks for interactions with the patient's other medicines.
Yes. It flags medicines likely to need prior authorization for a patient's insurance and suggests a covered option when one exists. It uses public drug price data so lower-cost choices rise when the benefit is similar.
Clinics can turn off whole groups of options they do not offer, such as controlled substances or acupuncture. Patients can say what they do not want to try, and the platform accounts for what a patient has already tried and how it worked.
Patients get their care plan in the EO web app, with no download required. The app handles intake, delivers the care plan you recommend, makes it easy to obtain the recommended treatments, collects ongoing plan feedback, and triages the patient intelligently as issues arise. We designed it with cancer patients to give them agency in managing their experience of cancer, reducing office calls and staff burden.
When a patient reports a serious warning sign, like a high fever, chest pain or new confusion, the platform alerts the care team right away. It never tries to manage a serious symptom on its own. It also predicts which patients are more likely to end up in the ER, so the platform and your team can monitor that group more closely.
No. It helps them make better, smarter decisions and takes lower-level, time-consuming tasks off their plate so they can focus on the patients who need them most. The goal is more proactive symptom management, smarter triage and fewer phone calls for your whole team.